Vaccine safety policy analysis in three European countries: the case of thimerosal.
Freed
Gary L
GL
Child Health Evaluation and Research (CHEAR) Unit, University of Michigan Medical Center, Ann Arbor 48109-0456, MI, USA. gfreed@umich.edu
Andreae
Margie C
MC
Cowan
Anne E
AE
Katz
Samuel L
SL
D003257:Consumer Product Safety; D003695:Delivery of Health Care / Q000458:organization & administration; D004339:Drug Compounding / Q000009:adverse effects; D005602:France; D006115:Greece; D017408:Guidelines as Topic; D006291:Health Policy; D006801:Humans; D017589:Immunization Programs; D007494:Ireland; D013849:Thimerosal / Q000009:adverse effects*; D014481:United States; D014484:United States Environmental Protection Agency; D014486:United States Food and Drug Administration; D014612:Vaccines / Q000009:adverse effects* / Q000494:pharmacology; D014944:World Health Organization
D014612:Vaccines; D013849:Thimerosal